RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 87.7% | 0.6% | 34.1% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 77.1% | 78.3% | 65.8% | 64.3% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -24% | -88.4% | -105.8% | -144.7% |
| Other Income/Exp. Net | £0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | £0 | -£0 | -£0 | -£0 |
| Net Income | £0 | -£0 | -£0 | -£0 |
| % Margin | 0% | -65.7% | -91.9% | -127.2% |
| EPS | 0 | -0.043 | -0.09 | -0.093 |
| % Growth | 100% | 52.5% | 3.1% | – |
| EPS Diluted | 0 | -0.043 | -0.09 | -0.093 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | £0 | -£0 | -£0 | -£0 |
| % Margin | 9.7% | -71.8% | -89.4% | -125.5% |